DAFTAR PUSTAKA

Abdul, E., Shuaib, H. 2012, P53 expression in ovarian tumors: (an immunohistochemical
study), Ann.Coll.Med. Mosul, vol. 38, no. 2, pp. 73-79.
Altman, AD, Nelson, GS, Ghatage, P, McIntyre, JB, Capper, D, Chu, P 2013, The
Diagnostic Utility of TP53 and CDKN2A to Distinguish Ovarian High-Grade
Serous Carcinoma from Low-Grade Serous Ovarian Tumors, Modern
Pathology, vol.26, pp. 1255-1263.
Arik, D and Kulacoglu, S 2011. p53, bcl-2, and nm23 Expressions in Serous Ovarian
Tumors: Correlatian with the clikical and Histophatological Parameters, Turkish
Journal of Pathology, vol. 27. pp. 38-45.
Aziz, MF 2009, Gynecological Cancer in Indonesia, J Gynecol Oncol, vol. 20, no. 1,
pp:8-10.
Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Anatomi, 2011, Kanker
di Indonesia tahun 2011 Data Histopatologik, Direktorat Jendral Pelayanan
Medik Departemen Kesehatan RI, Yayasan kanker Indonesia, Jakarta.
Bai, L and Zhu, G 2006, p53: Structure, Function and Therapeutic Applications, Journal
of Cancer Molecules, vol. 2, no. 2, pp. 141-154.
Berek, JS, Crum, C, Friedlander, M 2012. Cancer of the Ovary, Fallopian Tube, and
Peritoneum, International Journal of Gynecology & Obstetrics, vol. 97, pp.
S118-S129.
Bourdon, JC, Laurenzi, VD, Melino, G, Lane, D 2003, p53: 25 years of Reaserch
and More Question to Answer in : Cell Death and Differentiation, 10th ed, pp
397-399.
Centers for Disease Control and Prevention, US Departement of Health and Human
Services, 2011. [online] Available at:
http://app.nccd.cdc.gov/uscs/toptencancers.aspx# Accessed 15 November 2015.
Chambers, SK and Martinez, JD 2012, The Significance of p53 Isoform in Serous Ovarian
Carcinoma Cancer, Future Oncol, vo. 8, no. 6, pp. 683-686.
Chen, VW, Ruiz, B, Killeen, JL, Cote, TR, Wu, XC 2003. Pathology and Classification of
Ovarian Tumors, The American Cancer Society, vol.97, pp. 2631-2642.
Chene, G, Lambun, G, Bail-Carval, KL, Chabert, P, Tigaud, JD, Mellier, G 2015. From
the Ovary to the Fallopian Tube; A History of Ovarian Carcinogenesis,
Contemporary Gynecologyc Practice, pp. 143-155.
Choudhury, M, Seema, G, Mukta, P, Meenu, P 2012, A Cytohistological study of p53
overexpression in ovarian neoplasm, South Asian Jounal of Cancer, vol.1, pp.
59-65.
Clark, TG and Altman DG 2003, Developing a Prognostic Model in the Presence of
Missing Data: An Ovarian Cancer Case Study, Journal of Clinical
Epidemiology, vol. 56, pp. 28-37.
Corney, DC, Flesken-Nikitin, A, Chol, J, Nikitin, AY 2008, Role of p53 and Rb in
Ovarian Cancer, Adv Exp Med Biol, vol. 622, pp. 99-117.
 51

Daniilidis, A and Karagiannis, V 2007, Epithelial Ovarian Cancer. Risk Factors, Screening
and the Role of Prophylactic Oophorectomy, Hippokratia 2007, vol. 11, no. 2,
pp. 63-66.
Devouassoux-Shisheboran, M and Genestie, C 2015, Pathobiology of Ovarian
Carcinoma, Chinese Journal of Cancer, vol.34, pp. 50-55.
Diniz, PM, Carvalho, JP, Baracat, EC, Carvalho, FM 2011, Fallopian Tube Origin of
Supposed Ovarian High-Grade Serous Carcinomas, Clinics, vol.66, no. 1, pp.73-
76.
Ellenson, LH and Pirog, EC 2010, The Female Genital Tract, in Kumar, V, Abbas, AR,
Fausto, N, Aster, JC (eds.), Robbins and Cotran Pathologic Basic of Disease,
8ed, Saunders Elsevier, Philadelphia, pp. 1040-1062.
Ezzati, M, Abdullah, A, Shariftabrizi, A, Hou, J, Kopf, M 20014, Recent Advancements
in Prognostic Factors of Epithelial Ovarian Carcinoma, International Scolarly
Research Notices, vol. 2014, pp. 1-10.
Garner, EI, Garrett, AP, Berkowitz, RS, Horowitz, NS 2008, Natural History and
Detection of Ovarian Carcinoma, Glob Libr Womens Med, vol. 10246, pp. 1-19.
Gilks, CB 2011,Pathology of Serous Tumors, in Soslow, RA and Tornos, C (eds.),
Diagnostic Pathology of Ovarian Tumors, Springer, London, pp. 55-73.
Hamdi, EA and Saleem, SH 2012, P53 Expression in Ovarian Tumors: (An
Immunohistiochemical Study), Annals of the College of Medicine, vol. 38, pp.
73-79.
Havrilesky, 2003, Significance of p53 Mutation and p53 Overexpression in Advanced
Epithelial Ovarian Cancer-A Oncology Group Study, Journal of Clinical
Oncology, vol. 21, no. 20, pp. 3814-3825.
Jayson, GC, Kohn, EC, Kitchener, HC, Lederman, JA 2014, Ovarian Cancer, Lancet, vol.
384, pp.1376-1388.
Jelovac, D and Amstrong, DK, Recent Progress in the Diagnostic and Treatment of
Ovarian Cancer, American Cancer Society, vol. 61, pp. 183-203.
Jermal, A, Siegel, R, Xu, J, Ward, E 2010, Cancer Statistics, 2010, American Cancer
Society, vol. 60, pp. 277-298.
Kumar, V, Abbas, AK, Fausto, N, Aster, JC, 2015, Neoplasia, Kumar, V, Abbas, AR,
Fausto, N, Aster, JC (eds.), Robbins and Cotran Pathologic Basic of Disease,
9ed, Saunders Elsevier, Philadelphia, pp. 265-340.
Kumar, V, Abbas, AK, Fausto, N, Aster, JC, 2010, Tissue Renewal, Regeneration, and
Repair, Kumar, V, Abbas, AR, Fausto, N, Aster, JC (eds.), Robbins and Cotran
Pathologic Basic of Disease, 8ed, Saunders Elsevier, Philadelphia, pp.
Landen, CN, Birrer, MJ, Sood, AK 2008, Early Events in the Pathogenesis of Epithelial
Ovarian Cancer, Journal of Clinical Oncolog, vol. 24, pp. 995-1005.
Levine, AJ, Hu, W, Feng, Z 2006, The p53 Pathway: What Question Remain to be
Explored?, Cell Death and Differentiation, vol. 13, pp. 1027-1036.
Khandakar, B, Mathur, SR, Kumar, L, Kumar, S, Gupta, SD, Iyer, VK 2014, Tissue
Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant
Chemotherapy, Hindawi,vol.2014, pp. 1-9.
 52

Karst, AM and Drapkin, R 2010, Review Article: Ovarian Cancer Pathogenesis: A Model
in Evolution, Journal of Oncology, vol. 2010, pp. 1-13.
Kimman, M, Norman, R, Jan, S, Kingston, D, Woodward, M 2012, The Burden of Cancer
in Member Countries of the Association of Southeast Asian Nations (ASEAN),
Asian Pacific J Cancer Prev, vol. 13, pp. 411-420
Kurman, RJ and Shih, LM 2010, The Origin and Pathogenesis of Epithelial Ovarian
Cancer: A Proposed Unifying Theory, Am J Surg Pathol, vol. 34, pp. 433-443.
Landen, CN, Birrer, MJ, Sood, AK 2008, Early Events in the Pathogenesis of Epithelial
Ovarian Cancer, Journal of Clinical Oncolog, vol. 24, pp. 995-1005.
Lalwani A, Prasad, SR, Vikram, R, Shanbohogue, AK, Huettner, PC, Fasih, N 2011,
Histologic, Molecular, and Cytogenetic Features of Ovarian Cancer: Implication
for Diagnostic and Treatment, Radio Graphics, vol. 2011, pp. 625-646.
Latifi, A, Escalona, R, Quinn, MA, Thompsn, EW, Findlay, JK, Ahmed, N 2014, Distinct
Molecular Signature of Recurrent ovarian Tumor Cells Isolated from the ascites
of advanced stage serous ovarian cancer patients, Journal of Cancer Stem Cell
Research, vol. 2, pp. 1-20.
Lee, JY, Kim, HS, Suh, DH, Kim, MK, Chung, HH, Song, YS 2013, Ovarian Cancer
Biomarker Discovery Based on Genomic Approaches, Journal of Cancer
Prevention, vol. 18, pp. 298-312.
Li, J, Fadare, O, Xiang, L, Kong, B, Zheng, W 2012, Ovarian Serous Carcinoma: Recent
Concepts on Its Origin and Carcinogenesis, Journal of Hematology & Oncology,
vol. 5, pp. 2-11.
Longarce, TA and Wells, M 2014, Serous Tumor, in Kurman, RJ, Carcangiu, ML,
Herringtong, CS, Young, RH (eds.), WHO Classification of Tumours of Female
Reproductive Organs, IARC, Lyon, pp.15-24.
McCluggage, W 2011, Morphological Subtypes of Ovarian Carcinoma: A Review with
Emphasis on Factors Associated and Pathogenesis, Pathology, vol. 43, pp. 420-
432.
McLemore, MR, Miaskowski, C, Aouizerat, BE, Chen, LM 2009, Epidemiologic and
Genetic Factors Associated with Ovarian Cancer, Cancer Nurs, vol. 32, pp. 281-
290.
Mishra, SK and Crasta, JA 2010, An Immunohistochemical Comparison of P53 and BCL-
2 as Apoptotic and MIB as Proliferative Markers in Low-Grade and High-Grade
Ovarian Serous Carcinomas, Int J Gynecol Cancer,vol. 20, no. 4, pp. 537-541.
Nofech-Mozees, S, Khalifa, MA, Ismil, N, Saad, RS, Hanna, WM, Ghorab, Z 2008,
Immunophenotyping of Serous Carcinoma of Female Genital Tract, Modern
Pathology, vol. 21, pp.1147-1155.
Nucci, MR, Crum, CP, Lee, KR 2011, The Pathology of Pelvic-Ovarian Epithelial
(Epithelial-Stromal) Tumors, in Nucci, MR, Crump, CP, Lee, KR (eds.),
Diagnostic Gynecologic and Obstetric Pathology, 2nd ed, Saunders Elsevier,
Philadelphia, pp. 818-889.
Prat, J 2012, New Insights into Ovarian Cancer Pathology, Annal of Oncology, vol. 23,
pp. 111-117.
 53

Prat, J 2013, Stagging Classification for Cancer of the Ovary, Fallopian Tube, and
Peritonium, International Journal of Gynecology and Obstetrics, vol. 2013, pp.
1-5.
Psyrri, A, Kountourakis, P, Yu, Z, Papadimitriou, C 2007, Analysis og Protein Expression
Levels on Ovarian Cancer tissue Microarray Using Automated Quantitative
Analysis Elucidates Prognostic Patient Subsets, Annal of Oncology, pp. 1-7.
Ranade, KJ, Nerurkar, AV, Phulpagar, MD, Shirsat, NV 2009, Expression of survivin
and p53 proteins and their correlation with hormone receptor status in Indian
breast cancer patients, Indian Journals of Medical Sciences, vol. 63, no. 11, pp.
481- 490.
Rauf, S, Masadah, H 2009, The Prognostic Value of the p53 Gene Expression and
Mutation in Ovarian Cancer, Med J Indonesia, vol. 18, pp. 81-90.
Reade, CJ, McVey, RM, Tone, AA, Finlayson, SJ, McAlpine, JN, Fung-Kee-Jung, M 2014,
The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review
of a Paradgm Shift, Journal Obstetric Gynecology Cancer, vol. 36, pp. 133-140.
Rosai, J 2011, Female Reproductive System-Ovary, in Rosai, J (ed.), Rosai and
Ackermans Surgical Pathology, 10th ed, Mosby Elsevier, Philadelphia, pp 1553.
Sastroasmoro, S & Ismael, S 2008, Dasar-dasar metodologi penelitian klinis, Sagung
Seto, Jakarta, pp. 307, 314-5.
Seidman, JD, Cho, KR, Ronnett, BM, Kurman, RJ 2011, Surface Epithelial Tumors of the
Ovary, in Kurman, RJ, Ellenson, LH, Ronnett, BM (eds.), Blaunsteins
Pathology of the Female Genital Tract, 6 ed, Springer, London, pp. 703-702.
Shi, HR, Zhang, RT 2009, Expression and Significance of P53, P21WAF1 and
CDK1 Proteins in Epithelial Ovarian Cancer, Ai Zheng, vol. 28, no.8, pp. 882-
885.
Smolle, E, Taucher, V, Pichler, M, Petru, E, Lax, S, Haybaeck, J 2013, Targeting Signaling
Pathways in Epithelial Ovarian Cancer, Int. J. Mol. Sci, vol. 14, pp. 9536-9555.
Starvidi, ES, Huyen, Y, Sheston, EA, Halazonetis, TD 2005, The Three-Dimensional
Structure of p53, in Zambetti, GP (eds.),The p53 tumor suppressor pathway and
cancer, Springer, London, pp. 1-23.
Sundov, D, Caric, A, Mrklic, I, Gugic, D, Capkun, V, Hofman, LD, Mise, BP, Tomic, CS
2013, P53, MAPK, Topoisomerse II Alpha dan Ki67 Immunohistochemical
Expression and KRAS/BRAF Mutation in Ovarian Serous Carcinoma,
Diagnostic Pathology, vol. 8, pp.1-9.
Tung, KH, Goodman, MT, Wu, AH, McDuffie, K, Wilkens, LR 2003, Reproductive
Factors and Epithelial Ovarian Cancer Risk by Histologic Type: A Multiethnic
Case-control Study, American Journal of Epidemiology, vol. 158, pp. 629-638.
Vang R, Shih, IM, Kurman, RJ 2009, Ovarian Low-grade and High-grade Serous
Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features,
and Diagnostic Problems, Adv Anat Pathol, vol. 16, pp. 267-282.
Vogelstein, B, Lane, D, Levine, AJ 2000. Surfing the p53 Network. Nature, vol.
408, pp. 307-310.
 54

Weidner, N, Dabbs, DJ, Peterson, M 2009, Ovaries, in Weiner, N, Cote, RJ, Suster, S,
Weiss, LM (eds.), Modern Surgical Pathology, 2nd ed, Saunders Elsevier,
Philadelphia, pp. 1356-1407.
Winata, IGS, Suwiyoga, IK, Megadhana, IW 2014, AnExpression of Protein 53 (P53) did
not Correlate with Staging of Ovarian Cancer, Merit Research Journal of
Medicine and Medical Sciences, vol. 2, no. 9, pp. 192-195.